CAR T-cell therapy trial paused after two patient deaths

Celyad Oncology placed a voluntary pause on a clinical trial of CYAD-101 after two patients treated with the investigational chimeric antigen receptor T-cell therapy died.
CYAD-101 is a nongene-edited allogeneic CAR T-cell therapy that targets the natural killer group 2D ligand (NKG2DL).
The international, multicenter phase 1B KEYNOTE-B79 trial is evaluating CYAD-101 with concurrent FOLFOX chemotherapy followed by pembrolizumab (Keytruda, Merck) for patients with treatment-refractory metastatic colorectal cancer.
Celyad decided to pause the trial after receiving reports of two patients who died

Celyad Oncology placed a voluntary pause on a clinical trial of CYAD-101 after two patients treated with the investigational chimeric antigen receptor T-cell therapy died.
CYAD-101 is a nongene-edited allogeneic CAR T-cell therapy that targets the natural killer group 2D ligand (NKG2DL).
The international, multicenter phase 1B KEYNOTE-B79 trial is evaluating CYAD-101 with concurrent FOLFOX chemotherapy followed by pembrolizumab (Keytruda, Merck) for patients with treatment-refractory metastatic colorectal cancer.
Celyad decided to pause the trial after receiving reports of two patients who died